ASPREE-D: Aspirin for the prevention of depression in the elderly

Copyright © International Psychogeriatric Association 2016. Background:: Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling....

Full description

Bibliographic Details
Main Authors: Berk, M., Woods, R., Nelson, M., Shah, R., Reid, Christopher, Storey, E., Fitzgerald, S., Lockery, J., Wolfe, R., Mohebbi, M., Murray, A., Kirpach, B., Grimm, R., McNeil, J.
Format: Journal Article
Published: Cambridge University Press 2016
Online Access:http://hdl.handle.net/20.500.11937/19735
_version_ 1848750114911289344
author Berk, M.
Woods, R.
Nelson, M.
Shah, R.
Reid, Christopher
Storey, E.
Fitzgerald, S.
Lockery, J.
Wolfe, R.
Mohebbi, M.
Murray, A.
Kirpach, B.
Grimm, R.
McNeil, J.
author_facet Berk, M.
Woods, R.
Nelson, M.
Shah, R.
Reid, Christopher
Storey, E.
Fitzgerald, S.
Lockery, J.
Wolfe, R.
Mohebbi, M.
Murray, A.
Kirpach, B.
Grimm, R.
McNeil, J.
author_sort Berk, M.
building Curtin Institutional Repository
collection Online Access
description Copyright © International Psychogeriatric Association 2016. Background:: Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention. Method:: ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression. Results:: This paper presents the rationale for the study and presents a summary of the study design. Conclusions:: ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression.
first_indexed 2025-11-14T07:31:41Z
format Journal Article
id curtin-20.500.11937-19735
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T07:31:41Z
publishDate 2016
publisher Cambridge University Press
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-197352017-09-13T13:51:03Z ASPREE-D: Aspirin for the prevention of depression in the elderly Berk, M. Woods, R. Nelson, M. Shah, R. Reid, Christopher Storey, E. Fitzgerald, S. Lockery, J. Wolfe, R. Mohebbi, M. Murray, A. Kirpach, B. Grimm, R. McNeil, J. Copyright © International Psychogeriatric Association 2016. Background:: Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention. Method:: ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression. Results:: This paper presents the rationale for the study and presents a summary of the study design. Conclusions:: ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression. 2016 Journal Article http://hdl.handle.net/20.500.11937/19735 10.1017/S104161021600079X Cambridge University Press fulltext
spellingShingle Berk, M.
Woods, R.
Nelson, M.
Shah, R.
Reid, Christopher
Storey, E.
Fitzgerald, S.
Lockery, J.
Wolfe, R.
Mohebbi, M.
Murray, A.
Kirpach, B.
Grimm, R.
McNeil, J.
ASPREE-D: Aspirin for the prevention of depression in the elderly
title ASPREE-D: Aspirin for the prevention of depression in the elderly
title_full ASPREE-D: Aspirin for the prevention of depression in the elderly
title_fullStr ASPREE-D: Aspirin for the prevention of depression in the elderly
title_full_unstemmed ASPREE-D: Aspirin for the prevention of depression in the elderly
title_short ASPREE-D: Aspirin for the prevention of depression in the elderly
title_sort aspree-d: aspirin for the prevention of depression in the elderly
url http://hdl.handle.net/20.500.11937/19735